Obscure Chinese Stock Scams Dupe American Investors by the Thousands
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2025
0mins
Should l Buy FDS?
Source: WSJ
Investment Scam Overview: Braden Lindstrom, a college professor, was scammed out of $80,000 by an impersonator posing as a financial adviser, leading him to invest in Jayud Global Logistics, a small Chinese company whose stock price dramatically crashed after initially rising.
Market Manipulation Concerns: Wall Street experts highlight that this type of scam is common with small Chinese stocks, which are often susceptible to manipulation and easily accessible to U.S. investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FDS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FDS
Wall Street analysts forecast FDS stock price to rise
12 Analyst Rating
1 Buy
7 Hold
4 Sell
Hold
Current: 205.540
Low
253.00
Averages
295.91
High
326.00
Current: 205.540
Low
253.00
Averages
295.91
High
326.00
About FDS
FactSet Research Systems Inc. is a global financial digital platform and enterprise solutions provider. The Company's solutions deliver financial data, analytics, and open technology to global clients, including individual users. Its segments include the Americas, EMEA and Asia Pacific. It provides financial data and market intelligence on securities, companies, industries and people to enable its clients to research investment ideas and analyze, monitor and manage their portfolios. It supports various workflows, including investment research, quantitative research, portfolio management and trading, portfolio analytics, wealth management, ESG investing solutions, industry analysis and data solutions. It provides open and flexible technology offerings, including a configurable desktop and mobile platform, and comprehensive data feeds. Its technology also includes LogoIntern, a workflow tool to streamline the task of adding, organizing, and formatting logos into pitch decks.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JOYY Reports Q4 Non-GAAP Earnings of $1.34 per Share
- Earnings Highlight: JOYY reported Q4 non-GAAP earnings of $1.34 per diluted American depositary share on Tuesday, indicating stable profitability despite a complex market environment.
- Market Reaction: This performance exceeded analyst expectations, potentially leading to a positive impact on the company's stock price and boosting investor confidence, reflecting JOYY's ability to maintain profitability in a competitive landscape.
- Future Outlook: While the company did not provide specific future guidance in its earnings report, the stable earnings performance may lay a foundation for future growth strategies, attracting more investor interest.
- Industry Context: Given the current economic climate, JOYY's strong profitability could serve as a benchmark for other tech companies, further driving competition and innovation within the industry.
See More
Zumiez Reports Strong Q4 Earnings Surpassing Expectations
- Earnings Highlight: Zumiez reported fiscal Q4 earnings of $1.16 per diluted share, a significant increase from $0.78 in the same period last year, indicating strong performance in the retail market.
- Sales Growth: This earnings growth suggests that Zumiez successfully attracted more consumers amidst a competitive market environment, thereby enhancing its sales and market share.
- Investor Confidence: The positive earnings report is likely to bolster investor confidence in Zumiez, which may have a favorable impact on its stock price and further drive the company's future investment and expansion plans.
- Future Outlook: As consumer spending gradually recovers, Zumiez is expected to maintain its growth momentum in the upcoming quarters, particularly among younger consumer demographics, further solidifying its market position.
See More
Oncology Institute Reports Narrowed Q4 Loss
- Financial Overview: The Oncology Institute (TOI) reported a Q4 loss of $0.06 per diluted share late Thursday, indicating a narrowing of losses compared to previous quarters, which suggests some progress in cost control and operational efficiency.
- Market Reaction: Despite the reduced losses, market reactions may remain cautious as investors will focus on the company's future profitability and growth potential, particularly in the highly competitive oncology treatment sector.
- Strategic Adjustments: The company may need to further optimize its R&D spending and market strategies to address industry challenges and enhance its market share, especially in new drug development and clinical trials.
- Future Outlook: With increasing demand for innovative therapies in the industry, the Oncology Institute must establish a clear growth strategy to attract investors and achieve sustainable development.
See More
Adobe's Earnings Might Not Boost Stock Recovery Amid Significant AI Threats.
- Earnings Report Insight: Adobe's upcoming earnings report may indicate growth in monetization from artificial intelligence.
- Investor Concerns: Despite potential positive signs, investor fears regarding AI disruption could hinder stock recovery.
See More
Three High-Yield Food Stocks: Caution Advised by Wells Fargo.
- Food Stocks and Yields: There are many food stocks that offer attractive yields for investors.
- Caution Advised: Investors are encouraged to thoroughly evaluate these stocks, akin to reading a nutrition label, before making investment decisions.
See More
Dick's Sporting Goods Shares Climb After Earnings Report, but Mixed Outlook Limits Growth.
- Stock Performance: Shares of Dick’s Sporting Goods increased on Thursday following the release of better-than-expected quarterly results.
- Fiscal Guidance: The retailer provided mixed guidance for the current fiscal year, indicating uncertainty in future performance.
See More
JOYY Reports Q4 Non-GAAP Earnings of $1.34 per Share
- Earnings Highlight: JOYY reported Q4 non-GAAP earnings of $1.34 per diluted American depositary share on Tuesday, indicating stable profitability despite a complex market environment.
- Market Reaction: This performance exceeded analyst expectations, potentially leading to a positive impact on the company's stock price and boosting investor confidence, reflecting JOYY's ability to maintain profitability in a competitive landscape.
- Future Outlook: While the company did not provide specific future guidance in its earnings report, the stable earnings performance may lay a foundation for future growth strategies, attracting more investor interest.
- Industry Context: Given the current economic climate, JOYY's strong profitability could serve as a benchmark for other tech companies, further driving competition and innovation within the industry.
See More
Zumiez Reports Strong Q4 Earnings Surpassing Expectations
- Earnings Highlight: Zumiez reported fiscal Q4 earnings of $1.16 per diluted share, a significant increase from $0.78 in the same period last year, indicating strong performance in the retail market.
- Sales Growth: This earnings growth suggests that Zumiez successfully attracted more consumers amidst a competitive market environment, thereby enhancing its sales and market share.
- Investor Confidence: The positive earnings report is likely to bolster investor confidence in Zumiez, which may have a favorable impact on its stock price and further drive the company's future investment and expansion plans.
- Future Outlook: As consumer spending gradually recovers, Zumiez is expected to maintain its growth momentum in the upcoming quarters, particularly among younger consumer demographics, further solidifying its market position.
See More
Oncology Institute Reports Narrowed Q4 Loss
- Financial Overview: The Oncology Institute (TOI) reported a Q4 loss of $0.06 per diluted share late Thursday, indicating a narrowing of losses compared to previous quarters, which suggests some progress in cost control and operational efficiency.
- Market Reaction: Despite the reduced losses, market reactions may remain cautious as investors will focus on the company's future profitability and growth potential, particularly in the highly competitive oncology treatment sector.
- Strategic Adjustments: The company may need to further optimize its R&D spending and market strategies to address industry challenges and enhance its market share, especially in new drug development and clinical trials.
- Future Outlook: With increasing demand for innovative therapies in the industry, the Oncology Institute must establish a clear growth strategy to attract investors and achieve sustainable development.
See More
Adobe's Earnings Might Not Boost Stock Recovery Amid Significant AI Threats.
- Earnings Report Insight: Adobe's upcoming earnings report may indicate growth in monetization from artificial intelligence.
- Investor Concerns: Despite potential positive signs, investor fears regarding AI disruption could hinder stock recovery.
See More
Three High-Yield Food Stocks: Caution Advised by Wells Fargo.
- Food Stocks and Yields: There are many food stocks that offer attractive yields for investors.
- Caution Advised: Investors are encouraged to thoroughly evaluate these stocks, akin to reading a nutrition label, before making investment decisions.
See More
Dick's Sporting Goods Shares Climb After Earnings Report, but Mixed Outlook Limits Growth.
- Stock Performance: Shares of Dick’s Sporting Goods increased on Thursday following the release of better-than-expected quarterly results.
- Fiscal Guidance: The retailer provided mixed guidance for the current fiscal year, indicating uncertainty in future performance.
See More
